Analyst consensus rating
Innoviva Analyst Rating: Buy
INVA is rated Buy by 4 analysts with a $35.00 target. As of 2026-08-31.
Direct answer
Innoviva's consensus rating is Buy.
4 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $35.00.
Forecast evidence checked August 31, 2026.
Get free Innoviva email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $20.97
- Average price target
- $35.00
- High price target
- $46.00
- Low price target
- $18.00
- Low target gap
- -14.2%
- Target upside
- +66.9%
- High target gap
- +119.4%
- Target range width
- 133.5%
- Consensus rating
- Buy
- Analysts
- 4
- Evidence date
- August 31, 2026
- Valid through
- September 7, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Innoviva?
Innoviva has a verified Buy consensus. The same dataset has an average price target of $35.00.
How far are Innoviva's low and high targets from the recorded price?
The low target implies -14.2%, while the high target implies +119.4%.
How many analysts are included in Innoviva's consensus?
The verified consensus includes 4 analysts.
How is Innoviva's target upside or downside calculated?
The average target of $35.00 is divided by the recorded price of $20.97, then one is subtracted to produce +66.9%. This does not guarantee a future return.
When was Innoviva's analyst forecast verified?
The data was verified on 2026-08-31. The dataset is valid through 2026-09-07.